Literature DB >> 28222899

Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis.

Josee-Lyne Ethier1, Danielle N Desautels2, Arnoud J Templeton3, Amit Oza4, Eitan Amir5, Stephanie Lheureux4.   

Abstract

BACKGROUND: Presence of a high neutrophil-to-lymphocyte ratio (NLR) has been associated with increased mortality in several malignancies. Here, we quantify the effect of NLR on survival in patients with gynecologic cancers, and examine the effect of clinico-pathologic factors on its prognostic value.
METHODS: A systematic search of electronic databases was conducted to identify publications exploring the association of pre-treatment blood NLR with overall survival (OS) and event-free survival (EFS) among patients with ovarian, endometrial and cervical cancers. Data from studies reporting a hazard ratio (HR) and 95% confidence interval (CI) or a p-value (P) were weighted by generic inverse-variance and pooled in a random effects meta-analysis. Subgroup analyses were conducted according to primary tumor type. Meta-regression was performed to evaluate the influence of clinico-pathologic factors on the HR for OS and EFS. All statistical tests were two-sided.
RESULTS: Twenty-six studies comprising 10,530 patients were included. Studies used different cut-offs to classify high NLR (range 0.89 to 5.03). The median cut-off for high NLR was 2.95 among twenty-six studies reporting a HR for OS, and 2.79 in seventeen studies reporting EFS outcomes. NLR greater than the cut-off was associated with worse OS (HR 1.65, 95% CI=1.44 to 1.89; P<0.001) and EFS (HR 1.57, 95% CI=1.35 to 1.82; P<0.001). This association was present in all tumor types. Most studies were comprised of patients with both early-stage and advanced disease. In cervical cancer, significant associations between NLR and OS were observed in studies of early- and mixed-stage patients and regression analysis showed a greater magnitude of effect in patients with locally advanced disease and in those who received both chemotherapy and radiation.
CONCLUSIONS: High NLR is associated with an adverse OS and EFS in patients with gynecologic malignancies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Endometrial cancer; Neutrophil-to-lymphocyte ratio; Ovarian cancer; Overall survival; Prognosis

Mesh:

Year:  2017        PMID: 28222899     DOI: 10.1016/j.ygyno.2017.02.026

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  33 in total

1.  Pre-treatment neutrophils count as a prognostic marker to predict chemotherapeutic response and survival outcomes in glioma: a single-center analysis of 288 cases.

Authors:  Zhiliang Wang; Liyun Zhong; Guanzhang Li; Ruoyu Huang; Qiangwei Wang; Zheng Wang; Chuanbao Zhang; Baoshi Chen; Tao Jiang; Wei Zhang
Journal:  Am J Transl Res       Date:  2020-01-15       Impact factor: 4.060

2.  Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors.

Authors:  Innocenza Palaia; Federica Tomao; Anna DI Pinto; Angelina Pernazza; Giusi Santangelo; Nicoletta D'Alessandris; Lucia Manganaro; Antonio Arno; Violante DI Donato; Giorgia Perniola; Carlo Della Rocca; Pierluigi Benedetti Panici
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

3.  Neutrophils to lymphocytes ratio and platelets to lymphocytes ratio in pregnancy: A population study.

Authors:  Anat Hershko Klement; Efrat Hadi; Aula Asali; Tal Shavit; Amir Wiser; Einat Haikin; Yael Barkan; Tal Biron-Shental; Alona Zer; Yifat Gadot
Journal:  PLoS One       Date:  2018-05-22       Impact factor: 3.240

4.  Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Penile Squamous Cell Carcinoma Patients Undergoing Inguinal Lymph Node Dissection.

Authors:  Mounsif Azizi; Charles C Peyton; David C Boulware; Juan Chipollini; Timothy Juwono; Julio M Pow-Sang; Philippe E Spiess
Journal:  Eur Urol Focus       Date:  2018-06-22

5.  NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer.

Authors:  Claudia Marchetti; Marco D'Indinosante; Carolina Bottoni; Chiara Di Ilio; Stefano Di Berardino; Barbara Costantini; Angelo Minucci; Laura Vertechy; Giovanni Scambia; Anna Fagotti
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

6.  Circulating cell-free DNA content as blood based biomarker in endometrial cancer.

Authors:  Lucia Cicchillitti; Giacomo Corrado; Martina De Angeli; Emanuela Mancini; Ermelinda Baiocco; Lodovico Patrizi; Ashanti Zampa; Roberta Merola; Aline Martayan; Laura Conti; Giulia Piaggio; Enrico Vizza
Journal:  Oncotarget       Date:  2017-12-14

7.  The Relationship between Hematological Indices and Autoimmune Rheumatic Diseases (ARDs), a Meta-Analysis.

Authors:  Xuanyu Hao; Dongyang Li; Dan Wu; Ning Zhang
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

8.  5-Hydroxy-4'-Nitro-7-Propionyloxy-Genistein Inhibited Invasion and Metastasis via Inactivating Wnt/b-Catenin Signal Pathway in Human Endometrial Carcinoma Ji Endometrial Cells.

Authors:  Jun Bai; Xin Luo
Journal:  Med Sci Monit       Date:  2018-05-17

9.  Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients.

Authors:  Quan Zhou; Li Hong; Man-Zhen Zuo; Ze He
Journal:  Oncotarget       Date:  2017-08-10

10.  Immune correlates of therapy outcomes in women with cervical cancer treated with chemoradiotherapy: A systematic review.

Authors:  David S Lakomy; Juliana Wu; Dorothy Lombe; Emmanouil Papasavvas; Susan Citonje Msadabwe; Yimin Geng; Luis J Montaner; Elizabeth Chiao; Lilie L Lin
Journal:  Cancer Med       Date:  2021-06-12       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.